SG11202109645QA - Methods of treating al amyloidosis - Google Patents
Methods of treating al amyloidosisInfo
- Publication number
- SG11202109645QA SG11202109645QA SG11202109645QA SG11202109645QA SG 11202109645Q A SG11202109645Q A SG 11202109645QA SG 11202109645Q A SG11202109645Q A SG 11202109645QA SG 11202109645Q A SG11202109645Q A SG 11202109645QA
- Authority
- SG
- Singapore
- Prior art keywords
- patient
- antibody
- meters
- stage
- amyloidosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
- A61B5/1124—Determining motor skills
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T15/00—Three-dimensional [3D] image rendering
- G06T15/06—Ray-tracing
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T15/00—Three-dimensional [3D] image rendering
- G06T15/50—Lighting effects
- G06T15/506—Illumination models
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/026—Measuring blood flow
- A61B5/029—Measuring blood output from the heart, e.g. minute volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814252P | 2019-03-05 | 2019-03-05 | |
| US201962942722P | 2019-12-02 | 2019-12-02 | |
| PCT/IB2020/000186 WO2020178638A1 (en) | 2019-03-05 | 2020-03-05 | Methods of treating al amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109645QA true SG11202109645QA (en) | 2021-10-28 |
Family
ID=70476256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109645Q SG11202109645QA (en) | 2019-03-05 | 2020-03-05 | Methods of treating al amyloidosis |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11692024B2 (https=) |
| EP (2) | EP3934689B1 (https=) |
| JP (2) | JP7619953B2 (https=) |
| KR (1) | KR20220019656A (https=) |
| CN (1) | CN113811332A (https=) |
| AU (1) | AU2020231081A1 (https=) |
| BR (1) | BR112021017550A2 (https=) |
| CA (1) | CA3132780A1 (https=) |
| CL (1) | CL2021002318A1 (https=) |
| FR (1) | FR3111560B1 (https=) |
| IL (1) | IL286040A (https=) |
| JO (1) | JOP20210245A1 (https=) |
| MA (1) | MA55209A (https=) |
| MX (1) | MX2021010665A (https=) |
| PH (1) | PH12021552135A1 (https=) |
| SG (1) | SG11202109645QA (https=) |
| WO (1) | WO2020178638A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12021552135A1 (en) * | 2019-03-05 | 2022-08-31 | Prothena Biosciences Ltd | Methods of treating al amyloidosis |
| AU2021339851A1 (en) * | 2020-09-14 | 2023-04-13 | Caelum Biosciences, Inc. | Method of treating amyloidosis |
| TW202332465A (zh) * | 2021-01-29 | 2023-08-16 | 愛爾蘭商普羅希那生物科學有限公司 | 治療al類澱粉變性症之方法 |
| US20250345418A1 (en) * | 2022-01-11 | 2025-11-13 | Prothena Biosciences Limited | Methods of treating al amyloidosis |
| AR132344A1 (es) * | 2023-04-10 | 2025-06-18 | Medimmune Llc | Optimización de los dominios de unión al antígeno cd3 |
| TW202547553A (zh) * | 2024-02-06 | 2025-12-16 | 愛爾蘭商普羅希那生物科學有限公司 | 治療ａｌ類澱粉變性症之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| DK2237803T3 (en) | 2007-12-28 | 2015-10-05 | Prothena Biosciences Ltd | Treatment and prophylaxis of amyloidosis |
| DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| SG10201604104PA (en) | 2011-10-25 | 2016-07-28 | Prothena Therapeutics Ltd | Antibody formulations and methods |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| US10213506B2 (en) | 2014-08-26 | 2019-02-26 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| DK3827845T3 (da) | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| WO2018005967A1 (en) | 2016-06-30 | 2018-01-04 | Prothena Therapeutics Limited | Compositions for treating amyloidosis |
| US11382974B2 (en) * | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
| US12018069B2 (en) | 2018-06-28 | 2024-06-25 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for imaging amyloid deposits |
| AU2019429147B2 (en) | 2019-02-12 | 2024-11-14 | Prothena Biosciences Limited | Treatment of AL amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the CD38 cell membrane molecule on antibody-producing and other immune cells |
| PH12021552135A1 (en) * | 2019-03-05 | 2022-08-31 | Prothena Biosciences Ltd | Methods of treating al amyloidosis |
| TW202332465A (zh) | 2021-01-29 | 2023-08-16 | 愛爾蘭商普羅希那生物科學有限公司 | 治療al類澱粉變性症之方法 |
-
2020
- 2020-03-05 PH PH1/2021/552135A patent/PH12021552135A1/en unknown
- 2020-03-05 BR BR112021017550A patent/BR112021017550A2/pt unknown
- 2020-03-05 SG SG11202109645Q patent/SG11202109645QA/en unknown
- 2020-03-05 US US16/810,319 patent/US11692024B2/en active Active
- 2020-03-05 WO PCT/IB2020/000186 patent/WO2020178638A1/en not_active Ceased
- 2020-03-05 JP JP2021552586A patent/JP7619953B2/ja active Active
- 2020-03-05 EP EP20722638.2A patent/EP3934689B1/en active Active
- 2020-03-05 CN CN202080033593.5A patent/CN113811332A/zh active Pending
- 2020-03-05 AU AU2020231081A patent/AU2020231081A1/en active Pending
- 2020-03-05 CA CA3132780A patent/CA3132780A1/en active Pending
- 2020-03-05 EP EP25163966.2A patent/EP4582446A3/en active Pending
- 2020-03-05 MX MX2021010665A patent/MX2021010665A/es unknown
- 2020-03-05 KR KR1020217031814A patent/KR20220019656A/ko active Pending
- 2020-03-05 MA MA055209A patent/MA55209A/fr unknown
-
2021
- 2021-06-16 FR FR2106376A patent/FR3111560B1/fr active Active
- 2021-09-01 IL IL286040A patent/IL286040A/en unknown
- 2021-09-03 CL CL2021002318A patent/CL2021002318A1/es unknown
- 2021-09-05 JO JOP/2021/0245A patent/JOP20210245A1/ar unknown
-
2023
- 2023-05-08 US US18/313,792 patent/US12240894B2/en active Active
-
2025
- 2025-01-09 JP JP2025003299A patent/JP2025063135A/ja active Pending
- 2025-03-03 US US19/068,630 patent/US20250188159A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL286040A (en) | 2021-10-31 |
| JOP20210245A1 (ar) | 2023-01-30 |
| FR3111560A1 (fr) | 2021-12-24 |
| JP2025063135A (ja) | 2025-04-15 |
| WO2020178638A1 (en) | 2020-09-10 |
| EP3934689B1 (en) | 2025-04-23 |
| EP3934689A1 (en) | 2022-01-12 |
| US20250188159A1 (en) | 2025-06-12 |
| CN113811332A (zh) | 2021-12-17 |
| MX2021010665A (es) | 2021-12-10 |
| BR112021017550A2 (pt) | 2021-11-09 |
| US11692024B2 (en) | 2023-07-04 |
| JP2022522889A (ja) | 2022-04-20 |
| MA55209A (fr) | 2022-01-12 |
| EP4582446A2 (en) | 2025-07-09 |
| PH12021552135A1 (en) | 2022-08-31 |
| CL2021002318A1 (es) | 2022-05-06 |
| JP7619953B2 (ja) | 2025-01-22 |
| CA3132780A1 (en) | 2020-09-10 |
| KR20220019656A (ko) | 2022-02-17 |
| US12240894B2 (en) | 2025-03-04 |
| EP4582446A3 (en) | 2025-08-13 |
| US20200308260A1 (en) | 2020-10-01 |
| US20230331831A1 (en) | 2023-10-19 |
| AU2020231081A1 (en) | 2021-09-30 |
| FR3111560B1 (fr) | 2024-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202109645QA (en) | Methods of treating al amyloidosis | |
| CN107257806A (zh) | 用于治疗pvns的抗csf1r抗体 | |
| AU2017347822A1 (en) | Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibody | |
| KR20210089719A (ko) | Hla-감작된 환자에서 탈감작화 및 신장 이식의 개선을 위한 클라자키주맙의 용도 | |
| US20250084153A1 (en) | Methods of treating al amyloidosis | |
| US20250345418A1 (en) | Methods of treating al amyloidosis | |
| KR20250114942A (ko) | 보체-매개 질환의 치료에 사용하기 위한 인자 h에 융합된 항-c5 항체 | |
| WO2025170969A1 (en) | Methods of treating al amyloidosis | |
| HK40066935B (en) | An antibody for use in methods of treating al amyloidosis | |
| HK40066935A (en) | An antibody for use in methods of treating al amyloidosis | |
| US11912772B2 (en) | Anti-galectin-9 antibody and methods of use thereof | |
| CN121925268A (zh) | 疫苗组合物及其用途 | |
| EA048260B1 (ru) | Способы лечения al-амилоидоза |